Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
19.70 | 9 Cr | 12.44 | 2.30 | 0.00 | 18.34 | 25.02 | 12.89 | ||
1.92 | 8 Cr | 19.20 | 1.76 | 0.00 | 9.05 | 5.66 | 1.81 | ||
58.01 | 7 Cr | 14.39 | 0.84 | 0.00 | 5.12 | 7.05 | 3.99 | ||
12.00 | 7 Cr | 70.90 | 0.85 | 0.00 | 1.22 | 2.79 | 1.04 | ||
6.05 | 6 Cr | -1.42 | 0.30 | 0.00 | -14.93 | -17.41 | -17.71 | ||
18.53 | 6 Cr | -5.59 | 1.90 | 0.00 | — | — | 0.00 | ||
5.29 | 5 Cr | 44.33 | 0.52 | 0.00 | 1.11 | 1.49 | 1.16 | ||
| Median: 7 Co. | — | 12.00 | 7 Cr | 14.39 | 0.85 | 0.00 | 3.17 | 4.22 | 1.16 |
Board meeting agenda
Vivanza Biosciences scheduled a Board meeting on 18 Jun 2026 to authorize signing of FY2026 financial statements, appoint M/s Dharti Shah & Co. as internal auditor, appoint Mr. Hemant Parikh as Non‑Exec director, and move unverified shares to Unclaimed Suspense Account.
Board Meeting Intimation
Vivanza Biosciences will hold a Board meeting on 18‑Jun‑2026 to authorise signing of FY2025‑26 financial statements, note and appoint M/s Dharti Shah & Co as internal auditor, appoint a non‑exec director, and transfer unverified shares to unclaimed suspense.
Vivanza Biosciences Ltd (VIVANZA) is currently trading at 1.86 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vivanza Biosciences Limited is a pharmaceutical company focusing on both novel and generic pharmaceutical products. Established in 1982, it has faced challenges but rebranded to expand its market reach globally. The company has undertaken a significant capacity expansion project, tripling its production capabilities from 18 lac pa to 54 lac pa. Vivanza Biosciences conducted a public issue to raise funds for expansion, showcasing strategic growth ambitions. The acquisition of Vivanza Lifesciences Private Limited marks a strategic step in enhancing its product portfolio and market reach.
Over the past 52 weeks, Vivanza Biosciences Ltd has traded between a low of ₹1.52 and a high of ₹2.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vivanza Biosciences Ltd has a market capitalization of approximately 7.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vivanza Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7.68 Cr, Vivanza Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vivanza Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vivanza Biosciences Ltd is 19.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Vivanza Biosciences Limited is a pharmaceutical company focusing on both novel and generic pharmaceutical products.
Established in 1982, it has faced challenges but rebranded to expand its market reach globally.
The company has undertaken a significant capacity expansion project, tripling its production capabilities from 18 lac pa to 54 lac pa.
Vivanza Biosciences conducted a public issue to raise funds for expansion, showcasing strategic growth ambitions.
The acquisition of Vivanza Lifesciences Private Limited marks a strategic step in enhancing its product portfolio and market reach.
Pharmaceuticals & Biotechnology
Pharmaceuticals
7 Cr
Low Risk
18.6
34.1
-0.1
1.8
2.72
1.52
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
6
Neutral
4
Bullish
4
Bearish
18
Neutral
4
Bullish
24
Bearish
12
Neutral
0
Bullish
20
